ABSTRACT
-ORIGINAL ARTICLE

ISCHEMIA/REPERFUSION
Biochemical study of the effects of cilostazol in rats subjected to acute ischemia and reperfusion of hind limbs and prevention of recurrent cerebral stroke 9 .
We hypothesize that cilostazol inhibits platelet aggregation and promoting vasodilation could decrease the deleterious effects of ischemia and reperfusion syndrome. If administered at the onset of ischemia could reduce acute ischemic events, and consequently reduce renal injury after reperfusion.
The objective of this study is to assess the effect of cilostazol in rats submitted to acute ischemia and reperfusion of hind limbs through study of biochemical variables in blood and urine, since no experimental models in animals studies on the effectiveness of cilostazol in acute ischemia and reperfusion have been reported. Forty six male Wistar rats, ten months age and average weight of 300 grams were used.
Methods
This study was approved by the Ethics
Surgical technique
The animals were anesthetized and placed an orogastric tube.
Laparotomy was performed in 4 cm long. The abdominal aorta was ligated just below the renal artery with propylene 7.0 10 .
Proceeded to divided into two randomly groups: 
Ischemic time
After aortic ligature, started to measure ischemia time and proceeded to the closure of the laparotomy.
After four hours of ischemia relaparotomy was performed in order to remove the aortic ligature and then, closed.
Reperfusion time
After removing aortic ligature, started to measure time of reperfusion.
Two animals were excluded from the previous steps of the experiment because they died before the final reperfusion time.
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Forty-four animals underwent a second phase, remaining in the study.
Proceeded to the distribution of animals in four groups according to the time of reperfusion:
Group IA: 13 animals that received cilostazol with reperfusion time of two hours.
Group IIA: 12 animals receiving saline solution 0.9%, with time of two hours of reperfusion.
Group IB: ten animals receiving cilostazol with reperfusion time of six hours.
Group IIB: nine animals receiving saline solution 0.9%, with time of six hours of reperfusion.
Collection of blood and urine and euthanasia
Again the animals were anesthetized and proceeded to puncture the bladder and completing cardiac puncture euthanasia.
The secret allocation was obeyed.
For biochemical analysis were measured to mioglobulina, urea and creatinine, sodium and potassium in the blood and mioglobulina, urea and creatinine in urine.
When the sample showed a normal distribution, shown by the normality of Shapiro-Wilk test was used t Test for sample data from two independent samples, with p ≤ to 0.05 for significance.
When the sample did not show a normal distribution, we used nonparametric test for two independent samples, Mann-Whitney (Wilcoxon rank-sum test), with p ≤ to 0.05 for significance.
Results
The biochemical parameters studied, both in blood and in urine were not statistically significant change compared between groups with two to six hours of reperfusion, animals treated with cilostazol or not ( Tables 1, 2 and 3) . 
Discussion
The cilostazol has been widely used in the treatment of chronic peripheral arterial disease and in treatment of ischemic coronary artery disease due to its antiplatelet and vasodilatation
The therapeutic use of cilostazol in acute ischemia and its role in prevention of reperfusion syndrome has not been
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recommended. The lack of randomized controlled studies, using cilostazol in ischemia and reperfusion in rat kidney and muscle,
we have motivated the design of this research. In this study it was hypothesized that cilostazol might have efficacy in treating acute ischemia and would decrease the metabolic syndrome of reperfusion protects target organs such as muscle and kidney.
Experimental studies have demonstrated that cilostazol obtained a protective effect against ischemic injury in animal models when used in another organs than skeletal muscle and kidneys 11, 12 .
Several experimental studies had model and design similar to our study to investigate the effectiveness of other drugs in ischemia and reperfusion 6, 14, 15 .
An experimental study demonstrated that cilostazol reduces the oxidative stress of ischemia and reperfusion in rats The tissue injury caused by ischemia and reperfusion is described as early onset, and studies have shown that biochemical changes are observable after four hours of ischemia and 15 minutes of reperfusion 13 .
In this study, biochemical changes due to ischemia and reperfusion were observed in the blood in similar intensity in the animals receiving cilostazol and those who received only saline solution. These changes were independent of reperfusion time, since it did not differ significantly in the two groups and underwent six hours of reperfusion.
This may be due to the number of subjects used, which the analysis of a few animals per group, had no power to find statistically significant differences.
It was not possible to study the urinary levels of myoglobin and creatinine in groups of six hours of reperfusion due to insufficient amount of urine in the bladder of the animal at the time of collection.
Conclusion
Cilostazol had no protective effect on the kidney and the skeletal striated muscle in rats submitted to acute ischemia and reperfusion in this model.
